Thrombin generates previously unidentified C5 products that support the terminal complement activation pathway

Blood

Volumn 120, Issue 8, 2012, Pages 1717-1725

  Krisinger, Michael J ^a,b   Goebeler, Verena ^a,b   Lu, Zhen ^a   Meixner, Scott C ^a,b,c   Myles, Timothy ^d   Pryzdial, Edward L G ^a,b,c   Conway, Edward M ^a,b,c  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c CANADIAN BLOOD SERVICES   (Canada)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALTERNATIVE COMPLEMENT PATHWAY C3 C5 CONVERTASE; CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C5; COMPLEMENT COMPONENT C5A; COMPLEMENT COMPONENT C5B; THROMBIN;

ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOLYSIS; HUMAN; HUMAN EXPERIMENT; NORMAL HUMAN; PLASMA; PRIORITY JOURNAL; PROTEIN CLEAVAGE; PROTEIN DEGRADATION;

EID: 84865428866     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-02-412080     Document Type: Article

References (37)

1. Krem MM, Di Cera E. Evolution of enzyme cascades from embryonic development to blood coagulation. Trends Biochem Sci. 2002;27(2):67-74. (Pubitemid 34164321)
2. Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. Anesth Analg. 2009;108(5):1433-1446.
3. Morgan BP. The complement system: an overview. Methods Mol Biol. 2000;150:1-13.
4. Ricklin D, Lambris JD. Complement-targeted therapeutics. Nat Biotechnol. 2007;25(11):1265-1275. (Pubitemid 350089828)
5. Markiewski MM, Nilsson B, Ekdahl KN, Mollnes TE, Lambris JD. Complement and coagulation: strangers or partners in crime? Trends Immunol. 2007;28(4):184-192. (Pubitemid 46476881)
6. Frangogiannis NG, Smith CW, Entman ML. The inflammatory response in myocardial infarction. Cardiovasc Res. 2002;53(1):31-47. (Pubitemid 34020764)
7. Arumugam TV, Woodruff TM, Lathia JD, Selvaraj PK, Mattson MP, Taylor SM. Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience. 2009;158(3):1074-1089.
8. Ducruet AF, Hassid BG, Mack WJ, et al. C3a receptor modulation of granulocyte infiltration after murine focal cerebral ischemia is reperfusion dependent. J Cereb Blood Flow Metab. 2008;28(5):1048-1058. (Pubitemid 351589644)
9. Volcik KA, Ballantyne CM, Braun MC, Coresh J, Mosley TH, Boerwinkle E. Association of the complement factor H Y402H polymorphism with cardiovascular disease is dependent upon hypertension status: the ARIC study. Am J Hypertens. 2008;21(5):533-538. (Pubitemid 351589664)
10. La Bonte LR, Davis-Gorman G, Stahl GL, McDonagh PF. Complement inhibition reduces injury in the type 2 diabetic heart following ischemia and reperfusion. Am J Physiol Heart Circ Physiol. 2008;294(3):H1282-H1290. (Pubitemid 351468725)
11. Ganter MT, Brohi K, Cohen MJ, et al. Role of the alternative pathway in the early complement activation following major trauma. Shock. 2007;28(1):29-34. (Pubitemid 46956459)
12. Richards SJ, Hill A, Hillmen P. Recent advances in the diagnosis, monitoring, and management of patients with paroxysmal nocturnal hemoglobinuria. Cytometry B Clin Cytom. 2007;72(5):291-298. (Pubitemid 350194346)
13. Richards A, Kavanagh D, Atkinson JP. Inherited complement regulatory protein deficiency predisposes to human disease in acute injury and chronic inflammatory states: the examples of vascular damage in atypical hemolytic uremic syndrome and debris accumulation in age-related macular degeneration. Adv Immunol. 2007;96:141-177. (Pubitemid 350018719)
14. Noris M, Remuzzi G. Genetic abnormalities of complement regulators in hemolytic uremic syndrome: how do they affect patient management? Nat Clin Pract Nephrol. 2005;1(1):2-3.
15. Schrezenmeier H, Hochsmann B. Drugs that inhibit complement. Transfus Apher Sci. 2012;46(1):87-92.
16. Wetsel RA, Kolb WP. Expression of C5a-like biological activities by the fifth component of human complement (C5) upon limited digestion with non-complement enzymes without release of polypeptide fragments. J Exp Med. 1983;157(6):2029-2048. (Pubitemid 13060901)
17. Polley MJ, Nachman R. The human complement system in thrombin-mediated platelet function. J Exp Med. 1978;147(6):1713-1726. (Pubitemid 8372963)
18. Huber-Lang M, Sarma JV, Zetoune FS, et al. Generation of C5a in the absence of C3: a new complement activation pathway. Nat Med. 2006;12(6):682-687. (Pubitemid 43865238)
19. Amara U, Flierl MA, Rittirsch D, et al. Molecular intercommunication between the complement and coagulation systems. J Immunol. 2010;185(9):5628- 5636.
20. DiScipio RG, Smith CA, Muller-Eberhard HJ, Hugli TE. The activation of human complement component C5 by a fluid phase C5 convertase. J Biol Chem. 1983;258(17):10629-10636. (Pubitemid 14244323)
21. Amara U, Rittirsch D, Flierl M, et al. Interaction between the coagulation and complement system. Adv Exp Med Biol. 2008;632:71-79.
22. Higgins DL, Mann KG. The interaction of bovine factor V and factor V-derived peptides with phospholipid vesicles. J Biol Chem. 1983;258(10):6503- 6508. (Pubitemid 13106824)
23. Stone SR, Le Bonniec BF. Inhibitory mechanism of serpins: identification of steps involving the active-site serine residue of the protease. J Mol Biol. 1997;265(3):344-362. (Pubitemid 27110690)
24. Rawal N, Pangburn MK. Functional role of the noncatalytic subunit of complement C5 convertase. J Immunol. 2000;164(3):1379-1385. (Pubitemid 30067252)
25. Rawal N, Pangburn MK. C5 convertase of the alternative pathway of complement. J Biol Chem. 1998;273(27):16828-16835.
26. Krishnan V, Ponnuraj K, Xu Y, Macon K, Volanakis JE, Narayana SV. The crystal structure of cobra venom factor, a cofactor for C3- and C5-convertase CVFBb. Structure. 2009;17(4):611-619.
27. Mann KG, Brummel K, Butenas S. What is all that thrombin for? J Thromb Haemost. 2003;1(7):1504-1514.
28. Mann KG. Thrombin generation in hemorrhage control and vascular occlusion. Circulation. 2011;124(2):225-235.
29. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. Blood. 1996;88(9):3432-3445. (Pubitemid 26365577)
30. DiScipio RG, Linton SM, Rushmere NK. Function of the factor I modules (FIMS) of human complement component C6. J Biol Chem. 1999;274(45):31811-31818.
31. Rawal N, Pangburn MK. Formation of high affinity C5 convertase of the classical pathway of complement. J Biol Chem. 2003;278(40):38476-38483. (Pubitemid 37221742)
32. Hadders MA, Bubeck D, Roversi P, et al. Assembly and regulation of the membrane attack complex based on structures of C5b6 and sC5b9. Cell Rep. 2012;1:1-8.
33. Thai CT, Ogata RT. Complement components C5 and C7: recombinant factor I modules of C7 bind to the C345C domain of C5. J Immunol. 2004;173(7):4547-4552. (Pubitemid 39280686)
34. Thai CT, Ogata RT. Recombinant C345C and factor I modules of complement components C5 and C7 inhibit C7 incorporation into the complement membrane attack complex. J Immunol. 2005;174(10):6227-6232. (Pubitemid 40663814)
35. Huntington JA. Molecular recognition mechanisms of thrombin. J Thromb Haemost. 2005;3(8):1861-1872. (Pubitemid 41716573)
36. Esmon C. The roles of protein C and thrombomodulin in the regulation of blood coagulation. J Biol Chem. 1989;264:4743-4746. (Pubitemid 19092874)
37. Fredslund F, Laursen NS, Roversi P, et al. Structure of and influence of a tick complement inhibitor on human complement component 5. Nat Immunol. 2008;9(7):753-760. (Pubitemid 351859158)